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clinicians use to correctly classify patients at risk of devel-
oping adverse events. Assessment based on signs and
symptoms together with echocardiography is valuable but
insufﬁcient, and some circulating biomarkers have been
identiﬁed and developed for routine use. Among these areSee page 167natriuretic peptides, which provide information about
myocardial stretch, and are already acknowledged in HF
guidelines (4–6). Novel biomarkers reﬂective of other pa-
thophysiological pathways, such as ventricular remodeling
and ﬁbrosis, are promising, but their contribution must go
beyond information available from conventional assessment,
which already includes natriuretic peptides.
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JACC Vol. 63, No. 2, 2014 Bayes-Genis et al.
January 21, 2014:158–66 Gal-3 Versus ST2 for Risk Stratification in Heart Failure
159Two such biomarkers are commercially available and
approved by the U.S. Food and Drug Administration: soluble
ST2 and galectin-3 (Gal-3). ST2 is a member of the inter-
leukin-1 receptor family and exists in 2 forms, a transmembrane
receptor (ST2L) as well as a soluble decoy receptor (ST2) (7).
The ligand of ST2L is interleukin-33, which is involved in
reducing ﬁbrosis and hypertrophy in mechanically strained
tissues. In in vitro and in vivo models, ST2L transduces the
effects of interleukin-33, whereas excess soluble ST2 leads to
cardiac ﬁbrosis and ventricular dysfunction (8–10). Gal-3 is
a soluble beta-galactosidase–binding glycoprotein released by
activated cardiac macrophages (11,12). Released Gal-3 in the
myocardium, via a paracrine effect, stimulates proliferation
of myoﬁbroblasts and procollagen 1 deposition (13). Both
ST2 and Gal-3 are reﬂective of ﬁbrosis and cardiac
remodeling, key in HF pathophysiology, and strongly
related to outcomes (14,15). A comparative prognostic
analysis of both biomarkers using state-of-the-art statistics
currently recommended for biomarker implementation has
not been done. Accordingly, we performed a head-to-head
evaluation of ST2 and Gal-3 in a large real-life cohort with
a long-term follow-up. The value of the 2 biomarkers over
conventional assessment was measured in terms of iscri-
mination, calibration, and reclassiﬁcation analysis.Methods
Study population. From May 2006 to July 2010, ambu-
latory patients treated at a multidisciplinary HF unit were
consecutively included in the study in an outpatient setting,
as previously reported (16). In summary, patients were re-
ferred to the unit by cardiology or internal medicine de-
partments and, to a lesser extent, from the emergency or
other hospital departments. The principal referral criterion
was HF according to the European Society of Cardiology
guidelines irrespective of etiology, at least 1 HF hospita-
lization, or a reduced left ventricular ejection fraction
(LVEF).
Blood samples were obtained by venipuncture between
9:00 AM and 12:00 AM during conventional ambulatory
visits. After adequate centrifugation, the serum samples were
stored at –80C. ST2, Gal-3, and N-terminal pro–B-type
natriuretic peptide (NT-proBNP) were analyzed from the
same blood sample.
All participants provided written informed consent, and
the study was approved by the local ethics committee. All
study procedures were in accordance with the ethical stan-
dards outlined in the Declaration of Helsinki of 1975, as
revised in 1983.
Follow-up and outcomes. All patients were followed up at
regular pre-deﬁned intervals, with additional visits as required
in the case of decompensation, need for up-titration, or other
circumstances that necessitated closer follow-up. The regular
schedule of visits included a minimum of quarterly visits with
nurses, biannual visits with physicians, and elective visits
with geriatricians, psychiatrists, and rehabilitation physicians(14,16). Those who did not attend
the regular visit were contacted by
telephone.
A death was considered to be
from cardiovascular origin if it was
caused by: HF (decompensated
HF or treatment-resistant HF, in
the absence of another cause);
sudden death (unexpected death,
witnessed or not, of a previously
stable patient with no evidence of
worseningHFor anyother cause of
death); acute myocardial infarction
(directly related in time with acute
myocardial infarction, whether due
to mechanic, hemodynamic, or
arrhythmic complications); stroke
(associated with recently appearing
acute neurologic deﬁcit); proce-
dural (post-diagnostic or post-
therapeutic procedure death); and
other cardiovascular causes (e.g.,
rupture of an aneurysm, peripheral ischemia, or aortic
dissection).
Five-year all-cause and cardiovascular death and the
combined all-cause death or HF hospitalization were the
primary endpoints. Fatal events were identiﬁed from clinical
records or by reviewing the electronic clinical history of the
Catalan and Spanish Health databases.
ST2 assay. Soluble ST2 was measured from banked plasma
samples using a high-sensitivity sandwich monoclonal
immunoassay (Presage ST2 assay, Critical Diagnostics, San
Diego, California). This platform offers improved accuracy
in quantifying ST2 levels, particularly at lower concentra-
tions. The antibodies used in the Presage assay were
generated from recombinant protein based on the human
complementary deoxyribonucleic acid clone for the complete
soluble ST2 sequence (17). The ST2 assay had a within-run
coefﬁcient of <2.5%, a total coefﬁcient of variation of 4%,
and a limit of detection of 1.31 ng/ml.
Gal-3 assay. For Gal-3 measurement, we used an enzyme-
linked ﬂuorescent assay (BioMerieux ref. 411191) on
a mini-VIDAS analyzer (BioMerieux, France). The coefﬁ-
cient of variation for the assay was <10%, the linearity 3.3 to
100.0 ng/ml, and the limit of detection 2.4 ng/ml.
NT-proBNP assay. NT-proBNP levels were determined
using an immuno-electrochemiluminescence assay on the
Modular Analytics E 170 (Roche Diagnostics, Switzerland).
This assay has <0.001% cross-reactivity with bioactive
BNP, and in the constituent studies in this report, the assay
had inter-run coefﬁcients of variation ranging from 0.9% to
5.5% (18).
Statistical analysis. Categorical variables were expressed as
percentages. Continuous variables were expressed as the
mean  SD or median (interquartile range) according
to normal or skewed distribution. Survival analyses were
Table 1
Demographic and Clinical Baseline Characteristics
and Treatments During Follow-Up (N ¼ 876)
Age, yrs 70.2 (60.5–77.2)
Female 249 (28.4)
Etiology
Ischemic heart disease 457 (52.2)
Dilated cardiomyopathy 85 (9.7)
Hypertensive 81 (9. 2)
Valvular 103 (11.8)
Other 150 (17.1)
LVEF,% 34 (26–43)
eGFR, ml/min/1.73 m2 43.2 (29.7–59.8)
Sodium, mmol/l 139 (137–142)
Hemoglobin, g/dl 12.9  1.8
NYHA functional class
I 64 (7.3)
II 576 (65.8)
III 227 (25.9)
IV 9 (1.0)
Hypertension 534 (61.0)
Diabetes mellitus 315 (36.0)
Treatments (follow-up)
ACEI or ARB 786 (89.7)
Beta-blocker 767 (87.6)
Spironolactone/eplerenone 342 (39.0)
Loop diuretic 742 (84.7)
Digoxin 265 (30.3)
CRT 47 (5.4)
ICD 92 (10.5)
NT-proBNP, ng/l 1,398 (529–3,016)
Galectin 3, ng/ml 16.5 (12.6–22.7)
ST2, ng/ml 38.2 (30.8–50.9)
Values are median (IQR), n (%), or mean  SD.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker;
CRT ¼ cardiac resynchronization therapy; eGFR ¼ estimated glomerular ﬁltration rate;
ICD ¼ implantable cardioverter-deﬁbrillator; IQR ¼ interquartile range; LVEF ¼ left ventricular
ejection fraction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart
Association; ST2 ¼ high-sensitivity soluble ST2.
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160performed using Cox regression models. To fulﬁll the
assumption of linearity of the covariables Gal-3, ST2, and
NT-proBNP, the logarithmic function of Gal-3 and NT-
proBNP, and ST2 plus the quadratic term of ST2 were
used in the Cox models. Online Figure 1 shows the
smoothing spline estimates for 5-year all-cause death for
Gal-3 and ST2 nontransformed levels. ST2 analyses were
performed per every 10 ng/ml change. The following vari-
ables were incorporated into the reference model: age; sex;
LVEF (%); estimated glomerular ﬁltration rate (ml/min/
1.73 m2); New York Heart Association functional class;
presence of diabetes mellitus; ischemic etiology; hemoglobin
(g/dl); serum sodium (mmol/l); beta-blocker treatment;
angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker treatment; and NT-proBNP level. Gal-3
and ST2 were subsequently added to this model. Log-rank
tests for Kaplan-Meier survival curves were performed
using Gal-3 and ST2 quartiles.
We used different measurements of performance to test
the potential incremental prognostic value of these bio-
markers, as follows.
DISCRIMINATION. C-statistics summarize the diagnostic
discrimination. Discrimination refers to a model’s ability to
correctly distinguish 2 classes of outcomes. We used the
index of rank correlation, Somers D, which already incor-
porates information of censored data. C-statistics between
models were compared using the Mann-Whitney U test for
equality concordance.
CALIBRATION. 1) The D’Agostino-Nam version of the
Hosmer-Lemeshow calibration test was used to calculate a c2
value. Amodel is well calibrated when predicted and observed
values agree for any reasonable grouping of the observation
(no statistically signiﬁcant differences in the Hosmer-
Lemeshow test results). 2) The Bayesian information crite-
rion (BIC), the Akaike information criterion (AIC), and the
Brier score were calculated for each model. The AIC and BIC
are measures of the relative goodness of ﬁt of a statistical
model. The BIC penalizes free parameters more strongly than
does the AIC. No statistical tests compare different BIC,
AIC, or Brier score estimations, and lower values indicate
a better model. 3) The global goodness of ﬁt of the models
was evaluated by likelihood ratio tests. A signiﬁcant p value in
this test means that adding a new variable to the model
signiﬁcantly improves the accuracy of the model.
RECLASSIFICATION. We used the method described by
Pencina et al. (19). There are 2 main statistics to assess
reclassiﬁcation. Integrated discrimination improvement
(IDI) considers the changes in the estimated mortality
prediction probabilities as a continuous variable. Net
reclassiﬁcation improvement (NRI) requires a previous
deﬁnition of meaningful risk categories (we used tertiles for
the risk of death: <13.9%, 13.9% to 30.2%, and >30.2%).
NRI considers changes in the estimated mortality prediction
probabilities that imply a change from 1 category to another.Values of p < 0.05 from 2-sided tests were considered to
indicate statistical signiﬁcance. The analyses were performed
using the software R statistical package (version 2.11.1,
Foundation for Statistical Computing, Vienna, Austria).
Role of the funding source. Funding sources did not have
a role in study design; collection, analysis, and interpretation
of data; writing of the report; or the decision to submit the
paper for publication.Results
Of the 891 consecutive patients included from May 2006
to July 2010, Gal-3 and ST2 were available for 876, the
ﬁnal number included in this analysis. Median age was
70.2 years (interquartile range [IQR]: 60.5 to 77.2 years).
Table 1 shows the baseline characteristics of the entire
sample. The median follow-up time was 4.2 years (IQR: 2.6
to 6.4 years), during which 392 patients died. Follow-up for
alive patients was 5.9 years (IQR: 4.1 to 6.7 years). A total of
453 HF hospitalizations were registered from 198 patients.
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161Among cardiovascular causes of death (n ¼ 221), refractory
HF was responsible in 113 (51.1%) patients, sudden death
in 45 (20.4%) patients, and acute myocardial infarction in 20
(9%) patients. Five patients were lost to follow-up and
adequately censored.
Cox regression and survival. In the bivariate analysis, both
biomarkers were predictors of death from all cause as
continuous variables (log(Gal-3) hazard ratio [HR]: 2.69,
95% conﬁdence interval [CI]: 2.22 to 3.27, p < 0.001; ST2
HR: 1.45, 95% CI: 1.32 to 1.59, p < 0.001) and signiﬁ-
cantly predicted cardiovascular death (log(Gal-3) HR: 2.74,
95% CI: 2.12 to 3.54, p < 0.001; and ST2 HR: 1.55, 95%
CI: 1.31 to 1.84, p < 0.001). For interpretation of these
HR, Gal-3 values were normalized by log transformation,
whereas ST2 was normalized by adding its quadratic
transformation to nontransformed ST2 levels, and ST2
analyses were performed per every 10 ng/ml change (Online
Appendix). Figure 1 shows Kaplan-Meier survival curves
according to Gal-3 (Fig. 1A) and ST2 (Fig. 1B) quartiles.
No interaction was found between mineralocorticoid
antagonists and ST2 (p ¼ 0.778) or Gal-3 (p ¼ 0.339).
In multivariable analysis, log(Gal-3) was independently
associated only with all-cause but not with cardiovascular
death (Table 2), whereas ST2 remained strongly and inde-
pendently associated with both all-cause and cardiovascular
death (Table 2). When high-sensitivity cardiac troponin
T was included in the multivariable analysis, log(Gal-3)
lost the statistical signiﬁcance even for all-cause death
(Online Table 1).
Both biomarkers remained independently associated
with the combined endpoint (all-cause death or HF hospi-
talization): log(Gal-3) HR: 1.39, 95% CI: 1.06 to 1.83, p ¼
0.017; and ST2 HR: 1.18, 95% CI: 1.08 to 1.29, p < 0.001.
When high-sensitivity cardiac troponin T was included in
the multivariable analysis, log(Gal-3) lost the statistical
signiﬁcance (HR: 1.28, 95% CI: 0.96 to 1.70, p ¼ 0.088),
whereas ST2 remained statistically associated with thisFigure 1 Kaplan-Meier Survival Curves According to Gal-3 and ST2
(A) Survival according to galectin-3 (Gal-3) quartiles. (B) Survival according to ST2 quartcombined endpoint (HR: 1.19, 95% CI: 1.08 to 1.32, p <
0.001). Figure 2 shows Kaplan-Meier curves for the
combined endpoint according to Gal-3 (Fig. 2A) and ST2
(Fig. 2B) quartiles.
Performance metrics in risk prediction models.
DISCRIMINATION. C-statistics for the prediction of all-cause
death and cardiovascular death signiﬁcantly increased when
ST2 was incorporated into the reference model with estab-
lished mortality risk factors and NT-proBNP. It did not
increase for either endpoint when Gal-3 was the added
biomarker (Tables 3 and 4).
The same occurred for the combined end-point (all-cause
death or HF hospitalization): C-statistic 0.735 [0.711 to
0.759] for reference model, 0.742 [0. 719 to 0.765],
p ¼ 0.033 for the ST2 model, and 0.737 [0.713 to 0.761],
p ¼ 0.332 for the Gal-3 model.
CALIBRATION. The p values for the Hosmer-Lemeshow
statistics indicated good calibration for all the models except
for the model containing Gal-3 for all-cause mortality (p ¼
0.049). Brier scores, AIC, and BIC were lower in the models
that included ST2, both for all-cause mortality (Table 3) and
for cardiovascular death (Table 4). Global goodness of ﬁt was
better in models including ST2 than in the model with only
established mortality risk factors, as evaluated by likelihood
ratio tests for both all-cause (p < 0.001) (Table 3) and
cardiovascular death (p ¼ 0.007) (Table 4). The likelihood
ratio for models including Gal-3 was nonsigniﬁcant for
cardiovascular mortality (p ¼ 0.127) (Table 4).
RECLASSIFICATION. IDI (risk as a continuous variable)
increased signiﬁcantly with the addition of ST2 to the
reference model, both for all-cause (IDI: 1.5, p ¼ 0.003)
(Table 3) and cardiovascular death (IDI: 1.3, p ¼ 0.004)
(Table 4), but not with the addition of Gal-3 in any case
(Tables 3 and 4). NRI (reclassiﬁcation according to pre-
deﬁned risk categories) for all-cause death improved
only after inclusion of ST2 into the full-adjusted modeliles.
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162(ST2 NRI: 9.4, p < 0.001; Gal-3 NRI: 0.7, p ¼ 0.649)
(Table 3). For cardiovascular death, NRI improved mainly
for alive patients when ST2 was added to the reference
model (NRI alive: 4.6, p < 0.001). Gal-3 did not improve
but worsened the NRI for deceased patients (NRI
deceased: –4.2, p ¼ 0.047) (Table 4). Direct comparison
of ST2 and Gal-3 models revealed that ST2 signiﬁcantly
improved reclassiﬁcation over Gal-3 (Table 5).
Again, when we considered the combined endpoint (all-
cause death or HF hospitalization), Gal-3 did not improve
reclassiﬁcation (IDI: 0.3, 95% CI: –0.1 to 0.8, p ¼ 0.157;
NRI: 0.6, 95% CI: –3.1 to 4.3, p ¼ 0.739), whereas ST2
signiﬁcantly improved both reclassiﬁcation metrics (IDI:
1.2, 95% CI: 0.4 to 1.9, p ¼ 0.002; NRI: 5.4, 95% CI: 0.7 to
10.2, p ¼ 0.024).
The addition of high-sensitivity cardiac troponin T in the
baseline model did not change the signiﬁcant value of ST2
in discrimination and reclassiﬁcation metrics (Online Tables
2 to 4).
Discussion
This study highlights the importance of assessing the true
value of emerging cardiac ﬁbrosis biomarkers above and
beyond clinical risk factors and natriuretic peptides partic-
ularly in light of the newly obtained ST2 and Gal-3
American College of Cardiology/American Heart Associa-
tion class II recommendation for determination of prognosis
in chronic HF (20). ST2 and Gal-3 were directly compared,
and our ﬁndings demonstrate that: 1) both ST2 and Gal-3
were associated with an increased risk of all-cause
mortality, but only ST2 with cardiovascular mortality; and
2) ST2 signiﬁcantly reﬁned discrimination and reclassiﬁca-
tion analysis, whereas Gal-3 had negligible effects on
performance metrics in risk-prediction models.
The independent prognostic value of ST2 and Gal-3
was examined on top of 11 classical risk factors (age, sex,
New York Heart Association functional class, estimated
glomerular ﬁltration rate, LVEF, diabetes mellitus, sodium,
hemoglobin, ischemic etiology ofHF, angiotensin-converting
enzyme inhibitor/angiotensin II receptor blocker treatment,
and beta-blocker treatment) plus NT-proBNP. Previously,
results with Gal-3 concerning outcome prediction have been
conﬂicting whenever natriuretic peptides are incorporated
into the analysis. In a short series of 232 patients, Lok et al.
(21) found that Gal-3 was a signiﬁcant predictor of mortality
even after adjusting forNT-proBNP. By contrast, Felker et al.
(22) andGullestad et al. (23), in large series of ambulatory HF
patients with long-term follow-up, found that Gal-3 was
signiﬁcantly predictive of long-term outcomes only in
univariate analysis; this association did not persist after
adjustment for other predictors, especially NT-proBNP. On
the side of ST2, in all studied cohorts with or without addi-
tional biomarkers, including natriuretic peptides, ST2
unambiguously emerged as a cardinal HF risk stratiﬁer
(14,24–29). In the current study, the 2 biomarkers remained
Figure 2 Kaplan-Meier Curves for the Combined Endpoint (All-Cause Mortality or HF Hospitalization) According to Gal-3 and ST2
(A) Event-free survival according to galectin-3 (Gal-3) quartiles. (B) Event-free survival according to ST2 quartiles. HF¼ heart failure.
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163as independent variables for all-cause mortality, but only ST2
was retained in the subgroup of cardiovascular mortality. Our
data indicates that every 10 ng/ml increase in ST2 is associated
tow20% increase in risk.
The additional prognostic information gained by any
biomarker over an established risk model needs to be
determined using adequate statistical tools (30). At present,
a major problem in selecting a biomarker is the proportional
increase in economic burden, so any addition should be
justiﬁed by adequate discrimination, calibration, and
reclassiﬁcation analyses (31). First, value of Gal-3 and ST2
on discrimination metrics: Gal-3 did not signiﬁcantly
increase discrimination (as assessed by the C-statistic) of the
reference model. By contrast, incorporation of ST2 into
a fully adjusted model signiﬁcantly improved the C-statistic,
which signiﬁcantly rose up to 0.770 (p value relative to
reference model, 0.004). Second, calibration of the models:
The full set of calibration analyses used in this study to
conﬁrm correspondence of predicted and observed values
indicated that overall, the model with ST2 is more accurate.
In all models, the Hosmer-Lemeshow test was expected to
be nonsigniﬁcant; yet, the model that incorporated Gal-3
was signiﬁcant for all-cause mortality. The Brier score
measures the average squared deviation between predicted
probabilities for a set of events and their outcomes, so
a lower score represents higher accuracy. Given any 2 esti-
mated models, the model with the lower BIC, AIC, and
Brier scores is preferred. In this study, the Brier score, the
AIC, and the BIC were lower in the ST2 model. Third,
value of the studied biomarkers on reclassiﬁcation metrics:
The model with ST2 signiﬁcantly increased IDI and NRI
for all-cause and cardiovascular mortality. Gal-3 had negli-
gible or even deleterious effects on reclassiﬁcation. Indeed,
Gal-3 NRI for cardiovascular mortality reached signiﬁcance
in the opposite direction with a value of –4.2, which is
indicative of worsening patient reclassiﬁcation. Together,these main ﬁndings suggest that the pathways identiﬁed by
ST2 profoundly affect risk stratiﬁcation in the context of
chronic HF and that the incremental predictive value of
adding Gal-3 to existing clinical risk factors, particularly
above and beyond NT-proBNP, is marginal.
Fibrosis is a fundamental component of the adverse
structural remodeling of myocardium present in the failing
heart (32). Replacement ﬁbrosis appears at sites of previous
cardiomyocyte necrosis to preserve the structural integrity of
the myocardium, but not without adverse functional conse-
quences. Increased stress or injury to the myocardium due to
acute myocardial infarction, uncontrolled hypertension, and
other forms of myocyte damage can contribute to ﬁbrosis
and cardiac remodeling. Responses to acute and chronic
damage can involve recruitment of immune cells to the
myocardium; production of cell signaling proteins from
local perycites, mast cells, and macrophages, resulting in
activation of resident ﬁbroblasts and myoﬁbroblasts; and
the deposition of procollagen into the extracellular matrix,
which is irreversibly cross linked to collagen-generating
cardiac ﬁbrosis. A multitude of regulators are involved in
the pathophysiology of cardiac ﬁbrosis and include ST2
and Gal-3. Given the limited beneﬁt of Gal-3 observed in
our cohort of ambulatory chronic HF patients, in which
remodeling and ﬁbrosis may be at an advanced stage, it is
conceivable that Gal-3 could have a more prominent role
in earlier stages of ﬁbrosis pathobiology and ventricular re-
modeling. Indeed, recent studies found that higher levels of
Gal-3 are associated with increased risk for new-onset HF
in apparently healthy people (33); in addition, plasma Gal-3
is elevated in patients admitted with acute myocardial in-
farction and reduced ejection fraction at baseline (34). Gal-3
may be a modest complement to other HF biomarkers by
providing an “upstream” signal of myocardial ﬁbrotic state.
Nevertheless, much remains to be clariﬁed about Gal-3 at
different stages of HF. Nativi et al. (35) recently reported
Table 3 Performance of the Models for All-Cause Mortality at 5 Years
Reference Model Model With Gal-3 Model With ST2
Discrimination
C-statistic 0.757 0.760 0.770
(0.733 to 0.782) (0.735 to 0.785) (0.746 to 0.793)
Reference p ¼ 0.143 p ¼ 0.004
Calibration
H-L Chi-square: 8.6 Chi-square: 16.9 Chi-square: 14.2
p ¼ 0.48 p ¼ 0.049 p ¼ 0.12
Brier score 0.171 0.170 0.165
AIC 4,020 4,016 4,003
BIC 4,077 4,078 4,070
Likelihood ratio Reference p ¼ 0.032 p < 0.001
Reclassiﬁcation
IDI 0.2 (–0.2 to 0.6) 1.5 (0.5 to 2.5)
Reference p ¼ 0.288 p ¼ 0.003
NRIdall 0.7 (–2.4 to 3.9) 9.4 (4.8 to 14.1)
Reference p ¼ 0.649 p < 0.001
NRIddeceased –0.1 (–2.6 to 2.4) 4.4 (0.9 to 7.9)
Reference p ¼ 0.929 p ¼ 0.014
NRIdalive 0.8 (–1.2 to 2.9) 5.0 (2.0 to 8.1)
Reference p ¼ 0.143 p ¼ 0.001
Values are n or n (95% CI) unless otherwise indicated. Reference model includes age, female, ischemic etiology of heart failure, LVEF, NYHA
functional class, diabetes mellitus, eGFR, ACEI or ARB treatment, beta-blocker treatment, sodium, hemoglobin, NT-proBNP. Model with Gal-3:
Reference model þ Gal-3. Model with ST2: Reference model þ ST2. All p values versus the reference model.
AIC ¼ Akaike information criterion; BIC ¼ Bayesian information criterion; H-L ¼ Hosmer-Lemeshow test; IDI ¼ integrated discrimination
improvement; NRI ¼ net reclassiﬁcation improvement; other abbreviations as in Tables 1 and 2.
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164that serum Gal-3 levels stay elevated despite replacement of
diseased myocardium and reversal of HF state with heart
transplant. These ﬁndings suggest that Gal-3 is a systemic
biomarker rather than being speciﬁc to HF. By contrast, ST2
measurement provides a strong serologic overview of the
cumulative myocardial ﬁbrotic process and ultimately isTable 4 Performance of the Models for Cardiovas
Reference Model
Discrimination
C-statistic 0.776
(0.745 to 0.807)
Reference
Calibration
H-L Chi-square: 10.2
p ¼ 0.33
Brier score 0.127
AIC 2,251
BIC 2,308
Likelihood ratio Reference
Reclassiﬁcation
IDI
Reference
NRIdall
Reference
NRIddeceased
Reference
NRIdalive
Reference
Values are n or n (95% CI) unless otherwise indicated. Models as deﬁned in
Abbreviations as in Tables 1 to 3.a relevant addition to the predictive ability of the practicing
clinician.
Because progressive cardiac ﬁbrosis is a central aspect in
the progression of cardiac dysfunction as well as the
primary substrate for lethal arrhythmias and sudden death,
it is intuitive that a blood marker of cardiac ﬁbrosis wouldcular Mortality at 5 Years
Model With Gal-3 Model With ST2
0.778 0.783
(0.747 to 0.809) (0.753 to 0.813)
p ¼ 0.288 p ¼ 0.04
Chi-square: 5.3 Chi-square: 14.7
p ¼ 0.81 p ¼ 0.1
0.127 0.125
2,250 2,245
2,312 2,311
p ¼ 0.127 p ¼ 0.007
0.2 (–0.3 to 0.6) 1.3 (0.4 to 2.1)
p ¼ 0.447 p ¼ 0.004
–4.2 (–8.8 to 0.5) 2.4 (–2.5 to 7.2)
p ¼ 0.078 p ¼ 0.344
–4.2 (–8.3 to –0.1) –2.3 (–6.2 to 1.6)
p ¼ 0.047 p ¼ 0.254
<0.1 (–1.8 to 1.8) 4.6 (2.1 to 7.2)
p ¼ 0.998 p < 0.001
Table 3. All p values versus the reference model.
Table 5
Direct Comparison of Performance for All-Cause and Cardiovascular Mortality
at 5 Years of Models Containing Gal-3 and ST2
All-Cause Mortality Cardiovascular Mortality
Gal-3 vs. ST2 Gal-3 vs. ST2
Discrimination
C-statistic 0.760 0.770 0.778 0.783
(0.735 to 0.785) (0.746 to 0.793) (0.747 to 0.809) (0.753 to 0.833)
p ¼ 0.035 p ¼ 0.254
Calibration
H-L Chi-square: 16.9 Chi-square: 14.2 Chi-square: 5.3 Chi-square: 14.7
p ¼ 0.049 p ¼ 0.12 p ¼ 0.81 p ¼ 0.1
Brier score 0.170 0.165 0.127 0.125
AIC 4,016 4,003 2,250 2,245
BIC 4,078 4,070 2,312 2,311
Reclassiﬁcation
IDI 1.3 (0.2 to 2.4) 1.1 (0.1 to 2.1)
Reference p ¼ 0.019 Reference p ¼ 0.029
NRIdall 7.8 (2.5 to 13.1) 4.5 (–0.4 to 9.4)
Reference p ¼ 0.004 Reference p ¼ 0.074
NRIddeceased 3.4 (–0.9 to 7.6) 0.5 (–3.6 to 4.6)
Reference p ¼ 0.118 Reference p ¼ 0.800
NRIdalive 4.5 (1.3 to 7.7) 3.9 (1.4 to 6.5)
Reference p ¼ 0.005 Reference p ¼ 0.002
Values are n or n (95% CI) unless otherwise indicated. All models include age, female, ischemic etiology of heart failure, LVEF, NYHA functional class,
Diabetes mellitus, eGFR, ACEI or ARB treatment, beta-blocker treatment, sodium, hemoglobin, NT-proBNP. All p values versus the reference model.
Reference model ¼ clinical factors þ Gal-3; model with ST2 ¼ clinical factors þ ST2.
Abbreviations as in Tables 1 to 3.
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165be independently associated with cardiovascular mortality.
This study shows that increased serum levels of ST2 were
not only predictive of all-cause mortality but also of
cardiovascular mortality. A previous study has already
demonstrated the value of ST2 in predicting sudden cardiac
death in ambulatory patients with mild-to-moderate
chronic HF and left ventricular systolic dysfunction (36).
Those authors found that the prognostic value of ST2 was
independent of other clinical variables and, importantly,
complementary to NT-proBNP. At present, no single test
reliably predicts sudden death in patients with HF (37), but
the combination of ST2 and NT-proBNP markedly
improved risk stratiﬁcation to identify high- and low-risk
patients; this fact may have an important impact on clin-
ical decision making, particularly for delineating optimal
preventive strategies.
Study limitations. First, whether serial measurements of
both biomarkers at pre-deﬁned time points would have
improved risk stratiﬁcation was not incorporated into the
design and is beyond the scope of the present report. Se-
cond, with regard to imaging techniques, ultrasounds were
primarily used to characterize ventricular remodeling, and
cardiac magnetic resonance imaging was not routinely per-
formed or available to all patients. Finally, the population
was a general HF population treated at a speciﬁc and
multidisciplinary HF unit in a tertiary care hospital; most
patients were referred from the cardiology department and
thus were relatively young men with HF of ischemic etiology
and reduced LVEF. As such, these results cannot necessarily
be extrapolated to a global HF population. The low use ofimplantable cardioverter-deﬁbrillators in this consecutive
cohort is representative of HF management in Mediterra-
nean countries. It is possible that more widespread use of
implantable cardioverter-deﬁbrillators might change our
ﬁndings. We must also acknowledge that the estimation of
effect size from adding biomarker measurements to the
clinical model is limited.
Conclusions
The head-to-head comparison of 2 new-generation
ﬁbrosis biomarkers revealed that ST2 is an important
addition to established risk factors, whereas the additive
value of Gal-3 was trivial. The incorporation of ST2 into
clinical practice for the prediction of all-cause and car-
diovascular mortality should be readily contemplated by
the practicing clinician. Further studies should conﬁrm
whether this superiority of ST2 is present at all stages of
the HF continuum.
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